Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma

Assessment of ERBB2 (HER2) status in breast carcinomas has become critical in determining response to the humanised monoclonal antibody trastuzumab. The current joint College of American Pathologists and the American Society of Clinical Oncology guidelines for the evaluation of HER2 status in breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruver, Aaron M, Peerwani, Ziad, Tubbs, Raymond R
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921277/
https://www.ncbi.nlm.nih.gov/pubmed/20203220
http://dx.doi.org/10.1136/jcp.2009.062760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921277/
https://www.ncbi.nlm.nih.gov/pubmed/20203220
http://dx.doi.org/10.1136/jcp.2009.062760

Ejemplares similares